Amylin Pharmaceuticals has announced that it will collaborate with the Juvenile Diabetes Research Foundation to test a combination of Symlin and insulin in injectible form as a type 1 therapy.
Currently, people with type 1 diabetes who take Symlin and insulin inject them separately. The test will determine if taking the two together increases blood sugar control by reducing the number of separate daily injections, making it easier for type 1s to manage the disease.
Symlin (pramlintide acetate) is an artificial analog of amylin, which is a hormone the pancreas secretes into the bloodstream along with insulin after a meal. In people with diabetes, amylin may be deficient or non-existent.
Symlin works by promoting a sense of satiety, slowing gastric emptying-which helps with the absorption of glucose-and inhibiting glucagon secretion.
The Amylin Pharmaceuticals-JDRF collaboration is the second one that the two partners have entered over the past year. In November, they announced that they would test whether metreleptin, a leptin mimic, can improve blood sugar control to the point of lowering the daily insulin dose required by patients with diabetes.